TO THE EDITOR
The myelodysplastic syndromes (MDS) are a heterogeneous group of hematological disorders displaying the common characteristics of peripheral blood cytopenias, bone marrow (BM) (hyper)activity and the variable occurrence of karyotypic and leukemic evolution. MDS affects mainly older individuals and in some 30-50% of patients karyotypic aberrations are found. Leukemic progression occurs in about a third of cases and is a major cause of death. Specific karyotypic aberrations are known to be associated with poor outcome and leukemic transformation. The refined cytogenetic stratification of the International Prognostic Scoring System (IPSS) enabled clinicians to better predict disease evolution than was previously possible in the subgroups of the French-American-British (FAB) classification. 1, 2 However, especially in the low and intermediate-1 risk IPSS categories, where mostly normal or low-risk karyotypic changes are found, the outcome remains highly variable. 3 This has prompted investigators to search for disease characteristics which better predict for progressive disease. Multilineage dysplasia is associated with inferior outcome and has been incorporated into the new World Health Organization classification for MDS. 4 In addition, we have showed that histological parameters such as abnormal localization of immature myeloid precursors and increased CD34 immunostaining can effectively discriminate patients at risk for leukemic evolution and poor outcome in the subgroups of the IPSS. 3 We are currently conducting a retrospective analysis of prognostic factors in a large group of patients followed at our institution with MDS. We were therefore extremely interested in the preliminary report of Lo Vasco et al 5 in Leukemia, showing that a cryptic deletion of the inositidespecific phospholipase c (PI-PLC) b1 gene was frequent in MDS with normal karyotype and heralded a remarkably short survival compared to MDS patients without this deletion. The deletion was easily demonstrated by fluorescence in situ hybridization (FISH) using a probe specific for PI-PLCb1 and a subtelomeric probe for 20p.
We decided to apply the same FISH assay to screen a number of MDS patients with normal karyotypes at diagnosis, using standard method and RBA banding. FISH was applied according to our standard method. 6 We used the probe for PI-PLCb1 (PAC clone RPCIS 881E24 from P de Jong RPCI-5 PAC library) labeled with spectrum green (Vysis) in combination with a probe for the 20p subtelomeric region (PAC clone CTB106I1, Sanger) labeled with spectrum orange (Vysis). We used archival fixed cell suspension from cytogenetic analyses on BM performed at diagnosis and kept at À201C. At least 200 interphase nuclei and 1-10 metaphases were screened by two investigators.
In a subset of cases, we repeated the analysis during the leukemic phase.
Patient characteristics and evolution are summarized in Table 1 . Patients 1-13 were low-risk MDS cases progressing to excess BM blasts in five cases, whereas patient 14 presented with excess BM blasts and patients 15-33 progressed to acute myeloid leukemia (AML). All cases had normal karyotype in BM at diagnosis. Of note is that 24% of the cases showed cytogenetic evolution with acquisition of clonal changes preceding or at leukemic progression. In all cases, FISH analysis with the PI PLCb1/20p probe set showed a normal hybridization pattern in 97-99% of the nuclei and in the metaphases. A cryptic deletion of PI-PLCb1 could not be demonstrated in the investigated cases.
Our results are in sharp contrast with the results of Lo Vasco et al, 5 who detected a monoallelic deletion of PI-PLCb1 in four of nine patients with progressive MDS and in two of six patients with AML. A possible explanation could reside in the selection of cases. The only criterium the authors supply is 'normal karyotype', but no information is given on disease characteristics and risk factors.
It would be extremely useful to know the diagnosis according to the FAB classification and the IPSS score of the nine MDS cases with normal karyotype studied by Lo Vasco et al, 5 as well as any undisclosed selection criteria that might have been applied. The authors state that the 4 PI-PLCb1 deleted MDS patients died within 1-6 months after diagnosis from AML evolution. This was in contrast to the more than 30 months survival of their other five MDS cases, where AML evolution is not reported. Note, however, that the short survival of PI-PLCb1 deleted cases also incorporated their progression to AML. These short survivals are usual in elderly patients after developing AML from MDS. Accordingly in our 19 cases with leukemic progression, median survival from AML development was only 3 months (range 0-10 months), whereas median overall survival of these cases was 19 months. In our database of 4250 MDS cases with normal karyotype, rapid leukemic transformation to death was a rare occurrence. Only patient 22 in our series had a survival similar to the deleted cases of Lo Vasco et al. 5 Our patients 7 and 8 also died rapidly but not from leukemic transformation.
This suggests that the deleted MDS cases in the paper of Lo Vasco et al 5 were mostly RAEB-T cases or what is termed AML in the new WHO classification. In that case their finding might be of importance to identify a high grade MDS/AML population with a specific underlying pathobiology based on deletion of functions in the PI-PLCb1 gene. We repeated the FISH analysis with the PI PLCb1/20p probe set on six cases with archival material at time of leukemic progression, but without associated karyotypic evolution. These cases again showed no evidence of a cryptic deletion of PI-PLCb1 on the short arm of chromosome 20.
Although cases with normal karyotype generally have a better prognosis than most cases with chromosomal aberrations, there is some evidence that screening for cryptic rearrangements and deletions could change the risk status in a fraction of patients. 7 However, only a limited number of probes can be utilized in this regard, and the prognostic value of this approach is not yet established. Our small series, however, confirm the Correspondence value of sequential classical karyotyping during disease progression. 8 An abnormal karyotype developed in eight of our patients, usually preceding, and in every case associated with, leukemic evolution as observed in seven of 19 patients developing AML and one patient developing RAEB with monosomy 7.
In summary, screening of 33 cases of MDS with normal karyotype failed to detect a monoallelic deletion of PI-PLCb1 gene. All FAB classes and IPSS risk groups were represented. This seems to indicate that the cryptic deletion that appears to be associated with very short survival is a rare event in MDS and thus of limited utility as a prognostic marker. This letter is also a call to other groups to share their experience with the use of this marker.
